Clinical trial · Interventional
Enthesitis Assessment Before and After Anti-Tumor Necrosis Factor Treatment in Spondyloarthritis
Clinical and Ultrasonographic Enthesitis Assessment Before and After Anti-Tumor Necrosis Factor Treatment in Patients With Spondyloarthritis
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Biological therapies should be considered in patients with high disease activity despite nonsteroid antiinflammatory drug treatment. The first option among biological therapies is anti-Tumor Necrosis Factor (anti-TNF) drugs. In recent years, anti-TNF treatments have shown that clinical and ultrasonographic enthesitis may improve as well as disease activity, quality of life and acute phase reactants. In this prospective study, we aimed to evaluate the clinical and ultrasonographic evaluation of enthesitis and to determine its response to anti-TNF treatment in patients with SpA.In this prospective study, we aimed to evaluate the clinical and ultrasonographic evaluation of enthesitis and to determine its response to anti-TNF treatment in patients with SpA.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anti-Tumor Necrosis Factor Drugs | — | UNRESOLVED | — |
| Enthesitis | — | UNRESOLVED | — |
| Spondyloarthritis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| TNF Inhibitor | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Spondyloarthritis
- description
- Spondyloarthritis patients who was initiated TNF alfa blocker
- interventionNames
- Drug: TNF Inhibitor
Primary outcomes (1)
- measure
- change from ultrasonographic entesitis score at 3 months
- timeFrame
- before and 3 months after anti-TNF treatment
- description
- Madrid Sonographic Enthesitis Index was used to screen etheseal sites
Secondary outcomes (4)
- measure
- Change from disease activity
- timeFrame
- before and 3 months after anti-TNF treatment
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Spondyloarthritis patients were diagnosed according to 2009 Assessment of Spondyloarthritis International Society (ASAS) criteria Exclusion Criteria: * Severe cardiovascular and respiratory diseases, * Severe liver and kidney failure, * Pregnancy and lactation, * Active infection, * Malignancy, * Demyelinating diseases, * Systemic lupus erythematosus, * History of knee, elbow, foot and ankle surgery, * Fluoroquinolone, retinoid and fluoride use, * Local corticosteroid injection at the examination sites within the six weeks before evaluation * Peripheral neuropathy
References
Publications (0)
Data not yet available